RIGL Related Analyst Ratings
-
Jefferies Cuts Target on Rigel Pharmaceuticals (RIGL) on Fostamatinib Setback
-
Roth Capital Downgrades Rigel Pharmaceuticals (RIGL) to Neutral
-
Piper Jaffray Downgrades Rigel Pharmaceuticals (RIGL) to Neutral
-
Wells Fargo Downgrades Rigel Pharmaceuticals (RIGL) to Market Perform Following OSKIRA Study
-
BMO Capital Downgrades Rigel Pharmaceuticals (RIGL) to Market Perform
-
Citi Downgrades Rigel Pharmaceuticals (RIGL) to Neutral
-
UBS Starts Rigel Pharmaceuticals (RIGL) at Neutral
-
Jefferies Sees Huge Upside in Shares of Rigel Pharma (RIGL)
-
Roth Capital Starts Rigel Pharmaceuticals (RIGL) at Buy
-
Leerink Swann Starts Rigel Pharmaceuticals (RIGL) at Outperform; Top Biotech with Two Drivers
-
Canaccord Genuity Starts Rigel Pharmaceuticals (RIGL) at Hold
-
Citi Upgrades Rigel Pharmaceuticals (RIGL) to Buy
-
Jefferies Maintains a 'Buy' on Rigel Pharmaceuticals (RIGL); Update On R343 And Early Pipeline
-
JPMorgan Starts Rigel Pharmaceuticals (RIGL) at Overweight
-
BMO Starts Biotech Stocks: AMGN, HGSI, REGN, CELG at Outperform, AMLN, GILD, ARNA at Market Perform, BIIB at Underperform
-
Jefferies Maintains Positive Stance on Rigel Pharmaceuticals (RIGL)
-
Barclays Maintains an 'Overweight' on Rigel Pharmaceuticals (RIGL); Update from Management Meeting
-
Barclays Reiterates an 'Overweight' on Rigel Pharmaceuticals (RIGL); OSKIRA Trials on Track with OLE Data at ACR; Update on R343 Dev. Status Next
-
Wells Fargo Starts Rigel Pharmaceuticals (RIGL) at Outperform; Growing Enthusiasm For New Oral RA Therapies
-
ThinkEquity Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Buy
-
Piper Jaffray Initiates Coverage on Rigel Pharmaceuticals (RIGL) with an Overweight; Investor Apathy Creates Unique Opportunity
-
Jefferies & Co Initiates/Resumes Coverage on Pharma/Biotechnology Stocks
-
RBC Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
-
Citi Downgrades Rigel Pharmaceuticals (RIGL) to Hold
-
Boenning & Scattergood Upgrades Rigel Pharmaceuticals (RIGL) to Outperform
-
Rodman & Renshaw Starts Rigel Pharma (RIGL) at Market Outperform, Multi-Billion Drug Potential
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
RBC Upgrades Rigel Pharmaceuticals (RIGL) to Sector Perform
-
RBC Capital Downgrades Rigel Pharmaceuticals (RIGL) to Underperform
-
Collins Stewart Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Hold
-
Susquehanna Reiterates a Positive on Rigel Pharmaceuticals (RIGL), Lowers Price Target
-
RBC Downgrades Rigel Pharma (RIGL) to Sector Perform
-
Susquehanna Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Positive
-
Piper Jaffray Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Buy
-
RBC Capital Initiates Coverage on Rigel Pharmaceuticals (RIGL) with an Outperform
-
Citi Initiates Coverage on Rigel (RIGL) with a Buy
-
Stanford Group Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Buy
-
Lehman Bros. Upgrades Rigel Pharmaceuticals (RIGL) to Overweight
-
CIBC Starts Rigel Pharmaceuticals (RIGL) with a Sector Outperformer
-
Credit Suisse Starts Rigel Pharms (RIGL) at Outperform
-
Jefferies & Co Initiates Coverage on Rigel Pharmaceuticals (RIGL) with a Buy
-
Needham Highlights Biotech Companies Presenting at the Upcoming American Society of Hematology
-
CSFB downgrades RIGL to Neutral
-
Wachovia Starts RIGL at Outperform
-
JMP Securities Started RIGL at Market Outperform
Back to RIGL Stock Lookup
